


Supplementary Materials: Formulation and Biological Evaluation of Mesoporous Silica Nanoparticles Loaded with Combinations of Sortase A Inhibitors and Antimicrobial Peptides

Sitah Alharthi, Zyta M. Ziora, Taskeen Janjua, Amirali Popat, Peter M. Moyle

Table S1. The concentrations of the sortase A inhibitor (SrtAIs; TC, CUR, QC, and BR)-loaded MCM-41 and MCM-41-PO₃⁻ MSNs, AMPs (PEX, INDO, and MASTO), and their combinations used in the cell viability study. Red values are the MICs of each compound.

Compound	Concentrations (µg/mL)						
PEX	50.0	25.0	12.5	6.25	3.13	1.56	
INDO	150	75.0	37.5	18.8	9.38	4.69	
MASTO	25.0	12.5	6.26	3.13	1.57	0.78	
TC MCM-41	1000	500	250	125	62.5	31.3	
CUR MCM-41	500	250	125	62.5	31.3	15.6	
QC MCM-41	500	250	125	62.5	31.3	15.6	
BR MCM-41	1000	500	250	125	62.5	31.3	
TC MCM-41-PO ₃ ⁻	500	250	125	62.5	31.3	15.6	
CUR MCM-41-PO ₃ ⁻	250	125	62.5	31.3	15.6	7.81	
QC MCM-41-PO ₃ ⁻	500	250	125	31.3	31.3	15.6	
BR MCM-41-PO ₃ ⁻	500	250	125	62.5	31.3	15.6	
PEX + TC MCM-41	12.5 + 125	6.25 + 62.5	3.13 + 31.3	1.56 + 15.6	0.78 + 7.81	0.39 + 3.91	
PEX + BR MCM-41	12.5 + 62.5	6.25 + 31.3	3.13 + 15.6	1.56 + 7.81	0.79 + 3.91	0.39 + 1.95	
INDO + QC MCM-41	37.5 + 125	18.8 + 62.5	9.38 + 31.3	4.68 + 15.6	2.34 + 7.81	1.17 + 3.91	
MASTO + CUR MCM-41	25.0 + 62.5	12.5 + 31.3	6.25 + 15.6	3.13 + 7.81	1.56 + 3.91	0.78 + 1.95	
PEX + TC MCM-41-PO ₃ ⁻	12.5 + 62.5	6.25 + 31.3	3.13 + 15.6	1.56 + 7.81	0.79 + 3.91	0.39 + 1.95	
PEX + BR MCM-41-PO ₃ ⁻	12.5 + 62.5	6.25 + 31.3	3.13 + 15.6	1.56 + 7.81	0.79 + 3.91	0.39 + 1.95	
INDO + QC MCM-41-PO ₃ ⁻	37.5 + 125	18.8 + 62.5	9.38 + 31.3	4.68 + 15.6	2.34 + 7.81	1.17 + 3.91	

MCM-41



MCM-41-PO₃⁻




Figure S1. Size, polydispersity index (PDI), intensity mean, and zeta potential of MCM-41 and MCM-41 PO₃⁻ MSNs.




Figure S2. N_2 -physorption isothermal analysis and pore size distribution of SrtAl-loaded and non-loaded MCM-41 and MCM-41- PO_3^- MSNs.




Figure S3. (i) Wide and (ii) narrow RP-HPLC gradients and ESI-MS data for purified PEX, INDO, and MASTO AMPs.




Figure S4. MICs of PEX, INDO, and MASTO against *S. aureus* ATCC 25923, *E. coli* ATCC 25922, *P. aeruginosa* ATCC27853, and MRSA ATCC43300 using the BMD assay.




Figure S5. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S6. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S7. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S8. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S9. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S10. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S11. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S12. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S13. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S14. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S15. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S16. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S17. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41-PO₅⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S18. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41-PO₅⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC 25922 using checkerboard assay.




Figure S19. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41-PO₅⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S20. Effects of PEX, INDO, or MASTO on HEK-293 cell viability following 24 h incubation. Statistical analyses were performed using one-way ANOVA followed by Tukey's post-hoc test. No statistically significant differences were found ($p > 0.05$). Data is expressed as mean \pm SD ($n = 3$).




Figure S21. Fourier-transform infrared spectroscopy (FTIR) spectrum of the sortase A inhibitors (SrtAIs, TC, CUR, QC, and BR) alone and loaded into MCM-41 and MCM-41- PO_3^- , and their physical mixture with MCM-41 and MCM-41- PO_3^- .